In radiomics, the MRI characteristics of brain gliomas, such as the volumes of contrast enhancement, edema, and necrosis; sharpness of lesion boundaries; boundary shapes; and the ratio of the T2/FLAIR hyper-intense volume to the volume of contrast enhancement and necrosis, have been reported to predict the tumor grade, molecular markers representing genes (IDH1, p53, ATRX, and MGMT), the efficacy of chemoradiotherapy, and glioma patient survival (7, 13–17). This evidence concerns the gene MGMT and central nervous system cancer.